4.7 Review

Emerging Role of Non-Coding RNAs in Aortic Dissection

Journal

BIOMOLECULES
Volume 12, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/biom12101336

Keywords

aortic dissection; micro RNA; long non-coding RNA; circular RNA; biomarker; therapeutic target

Funding

  1. National Natural Science Foundation of China [81970253]
  2. Natural Science Foundation of Shandong Province [ZR2019ZD28]

Ask authors/readers for more resources

This article summarizes the mechanisms of non-coding RNAs (ncRNAs) in regulating aortic dissection (AD) and their clinical applications as biomarkers and therapeutic targets. Studies have shown that the dysregulation of ncRNAs contributes to the occurrence and development of AD, making ncRNAs a potential new field for AD treatment.
Aortic dissection (AD) is a fatal cardiovascular acute disease with high incidence and mortality, and it seriously threatens patients' lives and health. The pathogenesis of AD mainly includes vascular inflammation, extracellular matrix degradation, and phenotypic conversion as well as apoptosis of vascular smooth muscle cells (VSMCs); however, its detailed mechanisms are still not fully elucidated. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are an emerging class of RNA molecules without protein-coding ability, and they play crucial roles in the progression of many diseases, including AD. A growing number of studies have shown that the dysregulation of ncRNAs contributes to the occurrence and development of AD by modulating the expression of specific target genes or the activity of related proteins. In addition, some ncRNAs exhibit great potential as promising biomarkers and therapeutic targets in AD treatment. In this review, we systematically summarize the recent findings on the underlying mechanism of ncRNA involved in AD regulation and highlight their clinical application as biomarkers and therapeutic targets in AD treatment. The information reviewed here will be of great benefit to the development of ncRNA-based therapeutic strategies for AD patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available